Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:TNXP

Tonix Pharmaceuticals Q3 2026 Earnings Date & Estimates

Tonix Pharmaceuticals logo
$6.13 -0.51 (-7.68%)
Closing price 04:00 PM Eastern
Extended Trading
$6.20 +0.08 (+1.22%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tonix Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Tonix Pharmaceuticals in Q3 2026

Tonix Pharmaceuticals is expected to post earnings of -$2.4475 per share on revenue of $15.87 million. In the same quarter a year earlier Tonix Pharmaceuticals reported -$3.59 per share on revenue of $3.29 million. Tonix Pharmaceuticals last reported on August 10, 2026, posting -$2.44 per share and beating the -$2.64 consensus estimate. Tonix Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$2.4475
Expected Revenue
$15.87 million
Prior-Year EPS
-$3.59
Prior-Year Revenue
$3.29 million
Expected Revenue Growth
+382.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.44 (Beat by +$0.20)
Last Quarter Revenue
$13.54 million
EPS Beat Rate
2 of last 7 quarters

Prepare for the Q3 2026 Call

Tonix Pharmaceuticals Q3 2026 Earnings FAQ

Tonix Pharmaceuticals (NASDAQ:TNXP) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Tonix Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Tonix Pharmaceuticals to post earnings of -$2.4475 per share for Q3 2026.

The consensus revenue estimate for Tonix Pharmaceuticals is $15.87 million for Q3 2026.

Tonix Pharmaceuticals Earnings Headlines

Tonix Pharmaceuticals (NASDAQ:TNXP) vs. SAB Biotherapeutics (NASDAQ:SABS) Head to Head Review
October 12 at 7:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110257
Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095510
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 13 at 1:00 AM  |  Chaikin Analytics (Ad)
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083590
Tonix Pharmaceuticals Holding Corp (TNXP)
September 23, 2026  |  in.investing.comhttps://in.investing.com/equities/tonix-pharm-news
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tonix-pharmaceuticals-announces-second-major-110000969.html
See More Tonix Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company focused on developing medicines and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company combines small-molecule drugs, biologics, and vaccine platforms in its research and development programs.

Tonix’s pipeline has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for the management of fibromyalgia and other pain-related conditions. The company has also pursued therapies based on intranasal oxytocin for conditions such as obesity and neurodevelopmental disorders, as well as vaccine candidates intended to address diseases including smallpox, mpox, and COVID-19.

Tonix Pharmaceuticals was founded in 2007 and is headquartered in Chatham, New Jersey. The company’s programs are primarily developed through research, clinical testing, and collaborations, with potential applications in the United States and international markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.

View Tonix Pharmaceuticals Profile
Earnings Tools